On April 17, 2026 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, reported preclinical data that showed powerful synergies between its two lead assets and emerging and foundational standard-of-care anti-cancer agents. Both ACR-368, a CHK1/2 inhibitor currently in a registrational-intent Phase 2b study, and ACR-2316, a WEE1/PKMYT1 inhibitor currently in a Phase 1/2 study, showed strong synergy in combination with anti-PD-L1 checkpoint inhibition. Additionally, ACR-368 synergized with a Topo 1 inhibitor, a payload commonly used in ADCs. The data will be presented at the AACR (Free AACR Whitepaper) 2026 Annual Meeting being held in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to be presenting these highly actionable data, mechanistically derived from our AP3 platform, at AACR (Free AACR Whitepaper)," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon. "Our findings highlight attractive opportunities for future frontline development of ACR-368 and ACR-2316 in combination with immune checkpoint inhibitors and ADCs."

The posters can be found on the Acrivon website under "Posters and Presentations" or by using this LINK.

Poster Presentation Details:

Title Potent synergy between CHK1/2 inhibitor ACR-368 and the ADC payload topoisomerase 1 inhibitor: Rationale for ADC + ACR-368 combination therapy
Date and Time Sunday, April 19, 2026; 2:00 p.m. – 5:00 p.m. PT
Session Experimental and Molecular Therapeutics: DNA Damage and Repair 1
Poster Number 239

Title ACR-368 synergizes with PD-L1 blockade by coordinated activation of adaptive and innate immunity pathways to achieve robust anti-tumor efficacy
Date and Time Monday, April 20, 2026; 9:00 a.m. – 12:00 p.m. PT
Session Late-Breaking Research: Immunology 2
Poster Number LB152

Title Treatment with ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, combined with anti-PD-L1 induces complete tumor regression with durable immune memory
Date and Time Monday, April 20, 2026; 2:00 p.m. – 5:00 p.m. PT
Session Clinical Research: Combination Immunotherapies
Poster Number 3789

(Press release, Acrivon Therapeutics, APR 17, 2026, View Source [SID1234664515])